These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 19514618)
1. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study]. Filipovský J Vnitr Lek; 2009 May; 55(5):513-6. PubMed ID: 19514618 [TBL] [Abstract][Full Text] [Related]
2. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Fox K; Ford I; Steg PG; Tendera M; Ferrari R; Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088 [TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Fox K; Ferrari R; Tendera M; Steg PG; Ford I; Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146 [TBL] [Abstract][Full Text] [Related]
4. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial. Danchin N Therapie; 2009; 64(2):111-4. PubMed ID: 19664404 [TBL] [Abstract][Full Text] [Related]
5. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611 [TBL] [Abstract][Full Text] [Related]
6. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice. Bruguera Cortada J; Varela A Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882 [TBL] [Abstract][Full Text] [Related]
7. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I; J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188 [TBL] [Abstract][Full Text] [Related]
8. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction. Perry CM Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944 [TBL] [Abstract][Full Text] [Related]
9. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K; Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517 [TBL] [Abstract][Full Text] [Related]
10. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R; Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635 [TBL] [Abstract][Full Text] [Related]
11. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. ; Ferrari R; Ford I; Fox K; Steg PG; Tendera M Cardiology; 2008; 110(4):271-82. PubMed ID: 18595216 [TBL] [Abstract][Full Text] [Related]
12. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R Am Heart J; 2013 Oct; 166(4):654-661.e6. PubMed ID: 24093844 [TBL] [Abstract][Full Text] [Related]
13. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709 [TBL] [Abstract][Full Text] [Related]
14. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. Fasullo S; Cannizzaro S; Maringhini G; Ganci F; Giambanco F; Vitale G; Pinto V; Migliore G; Torres D; Sarullo FM; Paterna S; Di Pasquale P J Card Fail; 2009 Dec; 15(10):856-63. PubMed ID: 19944362 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study]. Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH; Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174 [No Abstract] [Full Text] [Related]
16. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L; Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500 [TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction. Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043 [TBL] [Abstract][Full Text] [Related]
18. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Ruzyllo W; Tendera M; Ford I; Fox KM Drugs; 2007; 67(3):393-405. PubMed ID: 17335297 [TBL] [Abstract][Full Text] [Related]
19. Ivabradine vs metoprolol in patients with acute inferior wall myocardial infarction-"Expanding arena for ivabradine". Priti K; Ranwa BL; Gokhroo RK; Kishore K; Bisht DS; Gupta S Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28423233 [TBL] [Abstract][Full Text] [Related]
20. Ivabradine in stable coronary artery disease without clinical heart failure. Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R; N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]